COVID's Reign Challenged: Inhaled Wonder Drug Unveiled!

A revolutionary inhaled drug, SNS812, is poised to redefine COVID-19 treatment.
Stunning clinical results reveal rapid viral clearance and accelerated symptom relief.
Global experts to witness groundbreaking data at a top-tier ATS 2025 presentation.

The battle against COVID-19 has a formidable new champion. SNS812, an innovative siRNA drug co-developed by Oneness Biotech and Microbio (Shanghai), is electrifying the medical world. This is no ordinary treatment; it's the world's first fully modified siRNA drug administered via aerosol inhalation, engineered to deliver a potent and broad-spectrum blow against the SARS-CoV-2 virus^{1, 7}.

Imagine breathing in a new era of recovery. Phase II clinical trial results are nothing short of remarkable: SNS812 significantly crushes viral load, speeds the resolution of debilitating symptoms like shortness of breath, and dramatically shortens the agonizing wait for smell and taste to return^{1, 7}. This breakthrough offers profound hope, with strong potential to prevent severe disease progression and even provide neuroprotective effects. Critically, its safety profile is excellent, with no serious adverse events reported in trials^{1, 3, 4}.

The world’s foremost experts in respiratory and infectious diseases are set to gather as SNS812 commands the spotlight at the prestigious 2025 American Thoracic Society (ATS) International Conference. Its selection for an oral presentation in a Mini Symposium—the conference's highest-tier session reserved for science of exceptional originality and global impact—is a thunderous affirmation of its game-changing potential^{1, 7}. SNS812 represents a beacon of hope and a testament to the power of precision antiviral therapy in humanity's ongoing fight for health.

COVID's Reign Challenged: Inhaled Wonder Drug Unveiled!

References

Stay Updated!